EQT concludes revised offer for Recipharm

EQT AB (publ) now owns a total of 97,364,503 shares, or approximately 96.4% of the share capital, and approximately 98.8% of the voting rights, in Recipharm AB (publ) following the close of its revised takeover offer for the Swedish pharmaceutical company.

EQT's Roar BidCo AB unit has initiated a compulsory acquisition of the remaining shares in Recipharm.

The last day of trading in the company's shares on Nasdaq will be March 5 and settlement of the shares tendered under EQT's revised offer during the extended period is expected to commence around March 3.